Skip to content

Glutamine supplementation for cystic fibrosis

Glutamine supplementation for cystic fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN22534872
Enrollment
44
Registered
2007-12-21
Start date
2008-01-01
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis Nutritional, Metabolic, Endocrine Cystic fibrosis

Interventions

1. Glutamine 21 g/day 2. Placebo Treatment will continue for eight weeks for both. Follow up will occur for this entire period and a telephone call will be made 4 weeks later.

Sponsors

University of Nottingham (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Over 14 years old, male and female 2. Forced expiratory volume in one second (FEV1) greater than 40% predicted or receive regular nebulised saline treatment 3. Colonisation with Pseudomonas

Exclusion criteria

Exclusion criteria: 1. Current pregnancy or breastfeeding 2. Recent pulmonary exacerbation in past month 3. Lung transplant 4. Recently diagnosed or uncontrolled diabetes 5. Cirrhosis or severe liver failure 6. Initiation of new pulmonary therapies in the past month

Design outcomes

Primary

MeasureTime frame
Change in inflammatory markers in induced sputum, measured at baseline and after eight weeks.

Secondary

MeasureTime frame
1. FEV1 2. Serum C-reactive protein (CRP) 3. Infectious load of Pseudomonas 4. Systemic blood neutrophil activity 5. Jensen clinical score All outcomes measured at baseline and after eight weeks.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026